A Phase 2 interventional study of rituximab [MabThera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-03.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 86th largest by enrollment of the 171 interventional ones that give a count, is one of 4 that started in 1997, is one of 94 in phase 2, and was the 141st registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 4 started in 1997.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is close to the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 41st largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 1997, is one of 8 in phase 2, and was the 31st registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma. Patients will receive once-weekly intravenous MabThera/Rituxan for 4 weeks; responding patients will be treated a second time in case of relapse (defined as progression after complete or partial response). The anticipated time on study treatment is \<3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [MabThera/Rituxan]
Drug page: Rituximab
375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR)
Percentage of participants with a CR, PR at the end of the first cycle of treatment (Week 4). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1.500/ microliter (µL), hemoglobin (Hb) \>12 grams per deciliter (g/dL), and platelets \>100,000/µL. PR was defined as a less than (\<) 50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts.
Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Number of Participants With a Clinical Response
Clinical response was defined as the best response after the first 4 weeks of treatment cycle by the following categories: CR, PR, minor response (MR), stable disease (SD), and progressive disease (PD). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.
Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Time to Best Response
The median time, in months, from start of the treatment (first application) until best response (PR or CR).
Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Duration of Remission
Median time, in months, between the documentation of CR or PR and PD in clinical responders.
Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Time to Progression
The median time, in months, from the start of treatment (first application) until detection of PD.
Time frame: Treatment start until progression of disease or last available follow-up. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Overall Survival (OS)
OS was defined as the time, in months, between enrollment into the study and death, due to any cause. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.
Time frame: Enrollment into study until end of follow-up or death. The median length of follow-up was 6.6 months (range: 0-97.8 months)
Number of Participants With a Clinical Response to Re-Treatment
Clinical response was defined as the best response after the second 4 weeks of treatment cycle by the following categories: CR, PR, MR, SD, and PD. CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.
Time frame: First application in the second treatment cycle until progression of disease. The median length of follow-up was 4.6 months (range: 0.5-20.6 months).
| Milestone | Rituximab |
|---|---|
| Started | 38 |
| 1st treatment cycle completed until pd | 30 |
| 2nd treatment cycle started | 5 |
| 2nd treatment cycle completed until pd | 3 |
| Completed | 21 |
| Not completed | 17 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 8 |
| Withdrew: Physician decision | 2 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Transformation to high-grade lymphoma | 1 |
Percentage of participants with a CR, PR at the end of the first cycle of treatment (Week 4). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1.500/ microliter (µL), hemoglobin (Hb) \>12 grams per deciliter (g/dL), and platelets \>100,000/µL. PR was defined as a less than (\<) 50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts.
| percentage of participants | Rituximab |
|---|---|
| Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) | 39.5 (24.0 to 56.6) |
Clinical response was defined as the best response after the first 4 weeks of treatment cycle by the following categories: CR, PR, minor response (MR), stable disease (SD), and progressive disease (PD). CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.
| participants | Rituximab |
|---|---|
| CR | 9 |
| PR | 6 |
| MR | 3 |
| SD | 16 |
| PD | 2 |
| Missing | 2 |
The median time, in months, from start of the treatment (first application) until best response (PR or CR).
| months | Rituximab |
|---|---|
| Time to Best Response | 1.9 (1.1 to 5.7) |
Median time, in months, between the documentation of CR or PR and PD in clinical responders.
| months | Rituximab |
|---|---|
| Duration of Remission | 12.7 (5.6 to 35.0) |
The median time, in months, from the start of treatment (first application) until detection of PD.
| months | Rituximab |
|---|---|
| Time to Progression | 6.6 (4.8 to 15.3) |
OS was defined as the time, in months, between enrollment into the study and death, due to any cause. Participants who were not reported as having died at the time of the analysis were censored using the date they were last known to be alive.
| months | Rituximab |
|---|---|
| Overall Survival (OS) | 49.6 (15.3 to NA) |
Clinical response was defined as the best response after the second 4 weeks of treatment cycle by the following categories: CR, PR, MR, SD, and PD. CR was defined as the complete disappearance of all objective disease findings, including enlarged lymph nodes, hepatomegaly, and splenomegaly for at least 4 weeks, and a normalization of blood counts with granulocytes \>1,500/μL, Hb \>12 g/dL, and platelets \>100,000/μL. PR was defined as \<50% regression of all measurable and evaluable lymphoma manifestations (sum of the products of the 2 largest diameters vertical to each other) for at least 4 weeks without the appearance of new manifestations, and normalization of blood counts. MR was defined as tumor regression ≥25% and \<50%. SD was defined as tumor regression \<25%, no new manifestations, and progression ≤25%. PD was defined as no new lymphoma associated symptoms or an increase in the size of manifestations by more than 25%.
| participants | Rituximab |
|---|---|
| CR | 1 |
| PR | 0 |
| MR | 0 |
| SD | 3 |
| PD | 0 |
| Missing | 1 |
Collected over Adverse events (AEs) were reported from the beginning of study treatment until PD or last available follow-up in the first or the second treatment cycle. The median length of follow up was 6.7 months (range: 0-97.8 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 10/38 (26.3%) | 34/38 (89.5%) |
| Event | Rituximab |
|---|---|
| LymphocytesBlood and lymphatic system disorders | 2/38 |
| Sinus tachycardiaCardiac disorders | 2/38 |
| AllergyImmune system disorders | 1/38 |
| DysrhythmiasCardiac disorders | 1/38 |
| Lethargy (fatigue, malaise)General disorders | 1/38 |
| InfectionInfections and infestations | 1/38 |
| HypoglycemiaMetabolism and nutrition disorders | 1/38 |
| Shortness of breath (including wheezing)Respiratory, thoracic and mediastinal disorders | 1/38 |
| Event | Rituximab |
|---|---|
| Fever in absence of infection (including drug fever)General disorders | 14/38 |
| Rigor/chills (grade 3 including cyanosis)General disorders | 12/38 |
| InfectionInfections and infestations | 12/38 |
| HeadacheNervous system disorders | 7/38 |
| Rash/itch (not due to allergy, including recall reaction)Skin and subcutaneous tissue disorders | 7/38 |
| PlateletsBlood and lymphatic system disorders | 6/38 |
| Metabolic: other (not specified)Metabolism and nutrition disorders | 6/38 |
| LymphocytesBlood and lymphatic system disorders | 5/38 |
| NauseaGastrointestinal disorders | 5/38 |
| Lethargy (fatigue, malaise)General disorders | 5/38 |
Intent to treat (ITT) population included all participants with at least 1 application of study treatment.
| Age, Continuous(years) | Rituximab |
|---|---|
| Median | 55 (26 to 75) |
| Age, Customized(participants) | Rituximab |
|---|---|
| Less Than or Equal to (≤) 18 Years | 0 |
| Between 18 and 65 Years | 32 |
| Greater Than or Equal to (≥) 65 Years | 6 |
| Sex: Female, Male(Participants) | Rituximab |
|---|---|
| Female | 25 |
| Male | 13 |
| Race (NIH/OMB)(Participants) | Rituximab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 38 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Rituximab |
|---|---|
| Germany | 38 |
| Ann Arbor stage(participants) | Rituximab |
|---|---|
| Stage III | 5 |
| Stage IV | 33 |
| Histological subtype(participants) | Rituximab |
|---|---|
| Follicular or centroblastic/centrocytic lymphoma | 32 |
| Other | 6 |
| B-Symptoms(participants) | Rituximab |
|---|---|
| Present | 14 |
| Absent | 24 |
6 further baseline measures are reported on the registry.
The record gives a start of Jan 1997, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 6 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab